Free Trial
NASDAQ:TVRD

Tvardi Therapeutics 8/14/2025 Earnings Report

Tvardi Therapeutics logo
$39.90 +2.53 (+6.77%)
As of 03:38 PM Eastern

Tvardi Therapeutics EPS Results

Actual EPS
-$1.00
Consensus EPS
-$0.51
Beat/Miss
Missed by -$0.49
One Year Ago EPS
N/A

Tvardi Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Tvardi Therapeutics Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Tvardi Therapeutics Earnings Headlines

BTIG biotech analyst holds a dinner meeting
A Huge Shift Is Underway in America
Wall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who predicted the 2008 crash and 2020 says today's soaring markets are NOT a bubble - they're something far stranger and more dangerous. He says it's about to change everything you know about money.tc pixel
Tvardi Therapeutics (TVRD) Receives a Buy from Piper Sandler
See More Tvardi Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Tvardi Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Tvardi Therapeutics and other key companies, straight to your email.

About Tvardi Therapeutics

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

View Tvardi Therapeutics Profile

More Earnings Resources from MarketBeat